These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32256521)

  • 21. Insight updating of the molecular hallmarks in ovarian carcinoma.
    Mota A; S Oltra S; Moreno-Bueno G
    EJC Suppl; 2020 Aug; 15():16-26. PubMed ID: 33240439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer.
    Zhao Y; Yang SM; Jin YL; Xiong GW; Wang P; Snijders AM; Mao JH; Zhang XW; Hang B
    J Oncol; 2019; 2019():3614207. PubMed ID: 31885574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
    Fumet JD; Lardenois E; Ray-Coquard I; Harter P; Joly F; Canzler U; Truntzer C; Tredan O; Liebrich C; Lortholary A; Pissaloux D; Leary A; Pfisterer J; Eeckhoutte A; Hilpert F; Fabbro M; Caux C; Alexandre J; Houlier A; Sehouli J; Sohier E; Kimmig R; Dubois B; Spaeth D; Treilleux I; Frenel JS; Herwig U; Le Saux O; Bendriss-Vermare N; du Bois A
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities.
    Bateman NW; Abulez T; Soltis AR; McPherson A; Choi S; Garsed DW; Pandey A; Tian C; Hood BL; Conrads KA; Teng PN; Oliver J; Gist G; Mitchell D; Litzi TJ; Tarney CM; Crothers BA; Mhawech-Fauceglia P; Dalgard CL; Wilkerson MD; Pierobon M; Petricoin EF; Yan C; Meerzaman D; Bodelon C; Wentzensen N; Lee JSH; ; Huntsman DG; Shah S; Shriver CD; Phippen NT; Darcy KM; Bowtell DDL; Conrads TP; Maxwell GL
    NPJ Precis Oncol; 2024 Mar; 8(1):68. PubMed ID: 38480868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
    Boussios S; Karathanasi A; Cooke D; Neille C; Sadauskaite A; Moschetta M; Zakynthinakis-Kyriakou N; Pavlidis N
    Diagnostics (Basel); 2019 May; 9(2):. PubMed ID: 31109041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
    Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and molecular changes in ovarian cancer.
    Hollis RL; Gourley C
    Cancer Biol Med; 2016 Jun; 13(2):236-47. PubMed ID: 27458531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
    Jones WD; Michener CM; Biscotti C; Braicu I; Sehouli J; Ganapathi MK; Ganapathi RN
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32156016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
    Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM
    Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
    An Y; Bi F; You Y; Liu X; Yang Q
    J Cancer; 2018; 9(21):4058-4071. PubMed ID: 30410611
    [No Abstract]   [Full Text] [Related]  

  • 35. AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization.
    Azzalini E; Tierno D; Bartoletti M; Barbazza R; Giorda G; Puglisi F; Cecere SC; Losito NS; Russo D; Stanta G; Canzonieri V; Bonin S
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
    Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas.
    Lin S; Wang C; Zarei S; Bell DA; Kerr SE; Runger GC; Kocher JA
    BMC Genomics; 2018 Nov; 19(1):841. PubMed ID: 30482155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 39. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    Lisio MA; Fu L; Goyeneche A; Gao ZH; Telleria C
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.